JP2012525397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525397A5 JP2012525397A5 JP2012508606A JP2012508606A JP2012525397A5 JP 2012525397 A5 JP2012525397 A5 JP 2012525397A5 JP 2012508606 A JP2012508606 A JP 2012508606A JP 2012508606 A JP2012508606 A JP 2012508606A JP 2012525397 A5 JP2012525397 A5 JP 2012525397A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- item
- deficiency
- formulation
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 59
- 238000009472 formulation Methods 0.000 claims description 53
- 230000007812 deficiency Effects 0.000 claims description 52
- 208000011580 syndromic disease Diseases 0.000 claims description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 38
- 230000006378 damage Effects 0.000 claims description 31
- 208000035475 disorder Diseases 0.000 claims description 29
- 102000014461 Ataxins Human genes 0.000 claims description 22
- 108010078286 Ataxins Proteins 0.000 claims description 22
- 208000014644 Brain disease Diseases 0.000 claims description 22
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 22
- 208000032274 Encephalopathy Diseases 0.000 claims description 22
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 22
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 22
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 22
- 208000002780 macular degeneration Diseases 0.000 claims description 22
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 20
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 19
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 19
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims description 19
- 239000000835 fiber Substances 0.000 claims description 19
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 19
- 208000017442 Retinal disease Diseases 0.000 claims description 17
- 208000014674 injury Diseases 0.000 claims description 17
- 230000000750 progressive effect Effects 0.000 claims description 17
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 16
- 208000030768 Optic nerve injury Diseases 0.000 claims description 16
- 206010038923 Retinopathy Diseases 0.000 claims description 16
- 230000001684 chronic effect Effects 0.000 claims description 16
- 208000018737 Parkinson disease Diseases 0.000 claims description 14
- 230000008733 trauma Effects 0.000 claims description 14
- LNOVHERIIMJMDG-KTWAZNHYSA-N 2-[(6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O LNOVHERIIMJMDG-KTWAZNHYSA-N 0.000 claims description 13
- 208000012268 mitochondrial disease Diseases 0.000 claims description 12
- 230000004770 neurodegeneration Effects 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 201000004569 Blindness Diseases 0.000 claims description 11
- 208000010412 Glaucoma Diseases 0.000 claims description 11
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 11
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 11
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims description 11
- 206010030875 ophthalmoplegia Diseases 0.000 claims description 11
- 230000004393 visual impairment Effects 0.000 claims description 11
- 208000027073 Stargardt disease Diseases 0.000 claims description 10
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 claims description 10
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 8
- 208000026072 Motor neurone disease Diseases 0.000 claims description 8
- 206010033799 Paralysis Diseases 0.000 claims description 8
- 208000035965 Postoperative Complications Diseases 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 8
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 8
- 238000002647 laser therapy Methods 0.000 claims description 8
- 208000005264 motor neuron disease Diseases 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- 208000021090 palsy Diseases 0.000 claims description 8
- 238000002428 photodynamic therapy Methods 0.000 claims description 8
- 208000032253 retinal ischemia Diseases 0.000 claims description 8
- 102000007371 Ataxin-3 Human genes 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 238000011476 stem cell transplantation Methods 0.000 claims description 7
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 6
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 claims description 5
- SFVAYPRWECRHTF-QRCIITMISA-N 2-[(6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-6-methylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(C)(O)CCC1=CC(=O)C=C(C)C1=O SFVAYPRWECRHTF-QRCIITMISA-N 0.000 claims description 5
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 claims description 5
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 claims description 5
- 235000019151 β-tocotrienol Nutrition 0.000 claims description 5
- 239000011723 β-tocotrienol Substances 0.000 claims description 5
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 claims description 5
- 208000006136 Leigh Disease Diseases 0.000 claims description 4
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 3
- 230000001919 adrenal effect Effects 0.000 claims description 3
- 208000001749 optic atrophy Diseases 0.000 claims description 3
- 210000004885 white matter Anatomy 0.000 claims description 3
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 2
- 239000003732 agents acting on the eye Substances 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 229940113601 irrigation solution Drugs 0.000 claims description 2
- 229940125702 ophthalmic agent Drugs 0.000 claims description 2
- 229930003802 tocotrienol Natural products 0.000 claims description 2
- 239000011731 tocotrienol Substances 0.000 claims description 2
- 235000019148 tocotrienols Nutrition 0.000 claims description 2
- 229940064063 alpha tocotrienol Drugs 0.000 claims 3
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims 3
- 235000019145 α-tocotrienol Nutrition 0.000 claims 3
- 239000011730 α-tocotrienol Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000010444 Acidosis Diseases 0.000 claims 1
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 claims 1
- 208000017507 Leigh syndrome Diseases 0.000 claims 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 206010068786 Overlap syndrome Diseases 0.000 claims 1
- 230000007950 acidosis Effects 0.000 claims 1
- 208000026545 acidosis disease Diseases 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 34
- 208000024891 symptom Diseases 0.000 description 7
- 208000027993 eye symptom Diseases 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 230000000642 iatrogenic effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 3
- 208000018769 loss of vision Diseases 0.000 description 3
- 231100000864 loss of vision Toxicity 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 235000019150 γ-tocotrienol Nutrition 0.000 description 3
- 239000011722 γ-tocotrienol Substances 0.000 description 3
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 3
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 208000028226 Krabbe disease Diseases 0.000 description 2
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 2
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 102000015782 Electron Transport Complex III Human genes 0.000 description 1
- 108010024882 Electron Transport Complex III Proteins 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21479509P | 2009-04-28 | 2009-04-28 | |
| US61/214,795 | 2009-04-28 | ||
| US31873710P | 2010-03-29 | 2010-03-29 | |
| US61/318,737 | 2010-03-29 | ||
| PCT/US2010/032621 WO2010126909A1 (en) | 2009-04-28 | 2010-04-27 | Formulation of tocotrienol quinones for the treatment of ophthalmic diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014235405A Division JP2015038154A (ja) | 2009-04-28 | 2014-11-20 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525397A JP2012525397A (ja) | 2012-10-22 |
| JP2012525397A5 true JP2012525397A5 (cg-RX-API-DMAC7.html) | 2013-07-11 |
Family
ID=42236620
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508606A Withdrawn JP2012525397A (ja) | 2009-04-28 | 2010-04-27 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| JP2014235405A Withdrawn JP2015038154A (ja) | 2009-04-28 | 2014-11-20 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| JP2016078793A Pending JP2016128523A (ja) | 2009-04-28 | 2016-04-11 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| JP2017152470A Pending JP2017193594A (ja) | 2009-04-28 | 2017-08-07 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014235405A Withdrawn JP2015038154A (ja) | 2009-04-28 | 2014-11-20 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| JP2016078793A Pending JP2016128523A (ja) | 2009-04-28 | 2016-04-11 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| JP2017152470A Pending JP2017193594A (ja) | 2009-04-28 | 2017-08-07 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20100273892A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2424494A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP2012525397A (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1013377A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2759984A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201101576A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011011310A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010126909A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033093A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| DK2471530T3 (en) * | 2005-06-01 | 2017-04-10 | Edison Pharmaceuticals Inc | REDOXACTIVE THERAPEUTIC AGENTS FOR THE TREATMENT OF MITOCONDARY DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| HUE028502T2 (en) | 2007-11-06 | 2016-12-28 | Edison Pharmaceuticals Inc | 4- (P-Quinonyl) -2-hydroxybutanamide derivatives for the treatment of mitochondrial diseases |
| EP2237664A4 (en) * | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| US8716527B2 (en) | 2008-03-05 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases |
| US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| LT3827815T (lt) | 2008-09-10 | 2023-10-10 | Ptc Therapeutics, Inc. | Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais |
| US10039722B2 (en) | 2008-10-14 | 2018-08-07 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| ES2553557T3 (es) | 2008-10-28 | 2015-12-10 | Edison Pharmaceuticals, Inc. | Proceso para la producción de alfa-tocotrienol y derivados |
| HUE037574T2 (hu) | 2009-04-28 | 2018-09-28 | Bioelectron Tech Corp | Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal |
| CN102548548B (zh) * | 2009-06-10 | 2017-09-01 | 米拓科技有限公司（卢森堡） | 用于医学和兽医学的眼科药物组合物 |
| US20110207828A1 (en) * | 2009-08-26 | 2011-08-25 | Miller Guy M | Methods for the prevention and treatment of cerebral ischemia |
| CA2797644A1 (en) * | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| JP2013523816A (ja) * | 2010-04-06 | 2013-06-17 | エジソン ファーマシューティカルズ， インコーポレイテッド | 毛細血管拡張性運動失調症の治療 |
| US20120295985A1 (en) * | 2010-11-19 | 2012-11-22 | Miller Guy M | Methods for improving blood glucose control |
| EP2714024B1 (en) | 2011-06-03 | 2018-10-03 | Mitotech SA | Oral formulations of mitochondrially-targeted antioxidants and their preparation and use |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| WO2013006736A1 (en) * | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
| WO2013006737A1 (en) * | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc. | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
| WO2013013078A1 (en) | 2011-07-19 | 2013-01-24 | Edison Pharmeceuticals, Inc. | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| EP2573063A1 (en) | 2011-09-23 | 2013-03-27 | DSM IP Assets B.V. | Process for preparing chiral quinone |
| US9629815B2 (en) | 2012-09-07 | 2017-04-25 | Bioelectron Technology Corporation | Benzoquinone derivatives for treating oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| CA2906145A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| WO2015183963A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| NZ733528A (en) | 2014-12-16 | 2021-07-30 | Ptc Therapeutics Inc | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| JP7117241B2 (ja) | 2015-12-16 | 2022-08-12 | ピーティーシー セラピューティクス， インコーポレイテッド | 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法 |
| CA3008849A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| US20190365705A1 (en) * | 2017-01-20 | 2019-12-05 | Ohio State Innovation Foundation | Topical tocotrienol compositions and methods of increasing skin stem cells |
| HUE066196T2 (hu) | 2018-10-17 | 2024-07-28 | Ptc Therapeutics Inc | 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére |
| CA3225266A1 (en) | 2021-07-08 | 2023-01-12 | Swathi PINNAMANENI | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
| WO2024259130A1 (en) * | 2023-06-16 | 2024-12-19 | Ptc Therapeutics, Inc. | Methods for increasing vatiquinone plasma exposure with food |
| WO2025024247A1 (en) * | 2023-07-21 | 2025-01-30 | Stealth Biotherapeutics Inc. | Methods, compositions and uses related to the treatment and prevention of leigh's syndrome |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5318993A (en) * | 1993-04-16 | 1994-06-07 | Bristol-Myers Squibb Company | Antihyperlipidemic benzoquinones |
| EP1378753B1 (en) * | 2002-07-01 | 2006-05-31 | Santhera Pharmaceuticals (Schweiz) GmbH | A screening method and compounds for treating Friedreich Ataxia |
| US7015243B2 (en) * | 2003-08-28 | 2006-03-21 | Allergan, Inc. | Cyclohexyl prostaglandin analogs as EP4-receptor agonists |
| WO2005033093A1 (en) * | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| US20050074447A1 (en) * | 2003-10-01 | 2005-04-07 | Papas Andreas M. | Treatment for diabetic microvascular and macrovascular complications |
| US8182990B2 (en) * | 2004-03-18 | 2012-05-22 | Rusk Intellectual Reserve Ag | Method for diagnosing or predicting susceptibility to optic neuropathy |
| DK2471530T3 (en) * | 2005-06-01 | 2017-04-10 | Edison Pharmaceuticals Inc | REDOXACTIVE THERAPEUTIC AGENTS FOR THE TREATMENT OF MITOCONDARY DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS |
| EP1986636B1 (en) * | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| WO2008157747A1 (en) * | 2007-06-21 | 2008-12-24 | The Jackson Laboratory | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders |
-
2010
- 2010-04-27 EA EA201101576A patent/EA201101576A1/ru unknown
- 2010-04-27 JP JP2012508606A patent/JP2012525397A/ja not_active Withdrawn
- 2010-04-27 WO PCT/US2010/032621 patent/WO2010126909A1/en not_active Ceased
- 2010-04-27 BR BRPI1013377A patent/BRPI1013377A2/pt not_active Application Discontinuation
- 2010-04-27 MX MX2011011310A patent/MX2011011310A/es not_active Application Discontinuation
- 2010-04-27 US US12/768,554 patent/US20100273892A1/en not_active Abandoned
- 2010-04-27 EP EP10715649A patent/EP2424494A1/en not_active Withdrawn
- 2010-04-27 CA CA2759984A patent/CA2759984A1/en not_active Abandoned
-
2013
- 2013-01-10 US US13/738,827 patent/US20140031433A1/en not_active Abandoned
-
2014
- 2014-11-20 JP JP2014235405A patent/JP2015038154A/ja not_active Withdrawn
-
2016
- 2016-04-11 JP JP2016078793A patent/JP2016128523A/ja active Pending
-
2017
- 2017-08-07 JP JP2017152470A patent/JP2017193594A/ja active Pending
- 2017-12-20 US US15/849,557 patent/US20180116978A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525397A5 (cg-RX-API-DMAC7.html) | ||
| JP2012525398A5 (cg-RX-API-DMAC7.html) | ||
| JP2012525399A5 (cg-RX-API-DMAC7.html) | ||
| SI2424495T1 (en) | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones | |
| AU2011245384B2 (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| AU2011245384B9 (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| EP2424360A1 (en) | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases | |
| JP2013525443A5 (cg-RX-API-DMAC7.html) | ||
| JP2017193594A (ja) | 眼科疾患を治療するためのトコトリエノールキノンの製剤 | |
| JP5345744B1 (ja) | 網膜疾患の予防、改善、又は治療剤 | |
| JP2023179418A (ja) | 近視の進行を制御し且つ／又は減少させるための医薬組成物 | |
| WO2008020032A8 (en) | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases | |
| JP6867288B2 (ja) | リファマイシンの眼科用組成物およびその使用 | |
| JP6820658B2 (ja) | ジピリダモールを用いる眼疾患の治療において使用するための組成物 | |
| US10226444B2 (en) | Tissue repair of the nasal mucosa and treatment of rhinitis with alpha-tocpherol compositions | |
| RU2017111579A (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
| IT201700022522A1 (it) | Composizione oftalmica per l’uso nella rigenerazione delle fibre nervose della cornea in soggetti che sono stati sottoposti ad un intervento di cheratoplastica | |
| RU2489146C1 (ru) | Способ лечения "сухой" формы возрастной макулярной дегенерации | |
| ES3034599T3 (en) | Water-soluble topical ophthalmic preparation containing lutein and production method thereof | |
| EP3171873B1 (en) | Composition comprising an ester of alpha-tocopherol for prevention and treatment of allergic rhinitis | |
| Pasyechnikova et al. | Serous pigment epithelium detachment associated with age-related macular degeneration: a possible treatment approach | |
| Garrigue et al. | A comparative study of latanoprost-cationic emulsion (Catioprost) and latanoprost aqueous solution (Xalatan) in preclinical efficacy and safety models | |
| Richter et al. | Age-related macular degeneration | |
| ITMI20080516A1 (it) | Formulazioni topiche per uso oftalmico per la prevenzione e al trattamento di stati infiammatori dell'occhio | |
| IT202100005777A1 (it) | Composizione per l’uso nel trattamento dell’occhio secco |